Drug intelligence / Profile preview

GLB-006

Development stage: Preclinical
Lead developer: GluBio Therapeutics
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

GLB-006 is a preclinical molecular glue degrader (MGD) developed by Hangzhou GluBio Pharmaceutical that targets NIMA-related kinase 7 (NEK7). NEK7 is a critical component required for the activation and assembly of the NLRP3 inflammasome. By facilitating the proteasomal degradation of NEK7, GLB-006 prevents the formation of the NLRP3 complex, thereby inhibiting the production of inflammatory cytokines such as IL-1β and IL-18. This therapeutic strategy is being explored for the treatment of various inflammatory and autoimmune conditions where NLRP3 overactivation plays a central role.

Targets

NEK7 (NIMA-related kinase 7)

Beyond the preview

Go deeper on GLB-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLB-006.

Explore the full profile